• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

ENBREL Indication Expanded

Article

The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.

Recent Videos
Related Content
Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions

Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Current Commonalities in Contact Dermatitis with Matthew Zirwas, MD

Current Commonalities in Contact Dermatitis with Matthew Zirwas, MD

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Picking the Perfect Atopic Dermatitis Therapy with Matthew Zirwas, MD

Picking the Perfect Atopic Dermatitis Therapy with Matthew Zirwas, MD

Article
Scientific Advancements in Atopic Dermatitis with Matthew Zirwas, MD

Scientific Advancements in Atopic Dermatitis with Matthew Zirwas, MD

Article
© 2024 MJH Life Sciences

All rights reserved.